Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

Cancer - 1 May 2024

Van Not Olivier J, van den Eertwegh Alfons J M, Haanen John B, van Rijn Rozemarijn S, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan Willem W B, Hospers Geke A P, Kapiteijn Ellen, Bloem Manja, Piersma Djura, Stevense-den Boer Marion, Verheijden Rik J, van der Veldt Astrid A M, Wouters Michel W J M, Blokx Willeke A M, Suijkerbuijk Karijn P M

Abstract excerpt

BACKGROUND: Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. METHODS: Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retrieved from the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for both first...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38198485
DOI: 10.1002/cncr.35178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.PMID 38198485Read ↗

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read ↗

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.Semantic proximity Read ↗

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.Semantic proximity Read ↗

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.Semantic proximity Read ↗

Melanoma: BRAFi Rechallenge.Semantic proximity Read ↗

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read ↗

Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.Semantic proximity Read ↗

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitorSemantic proximity Read ↗

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.Semantic proximity Read ↗

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.Semantic proximity Read ↗

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.Semantic proximity Read ↗

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.